An innovative treatment for bladder cancer successfully prevented the recurrence of tumors and improved survival rates following surgery.

Credit: Getty Images. Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children. Pedmark ® (sodium thiosulfate) is now available to reduce ...

Patients with cancer who received prophylactic intravenous (IV) magnesium before starting cisplatin had a lower risk for cisplatin-associated acute kidney injury (AKI) than those who did not receive ...

Stocks of cisplatin are now able to meet demand for the widely used chemotherapy drug that had been in short supply in the U.S. over the last year, the FDA's top official said. FDA Commissioner Robert ...

Cisplatin-based chemotherapy regimens provide a survival benefit for patients with advanced or metastatic urothelial carcinoma of the bladder. Clinicians should follow established criteria for ...

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers. Background: Radical surgical resection ...

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. Like ...

Please provide your email address to receive an email when new articles are posted on . Only about 7% of patients with cancer in the United States may benefit from genome-driven care. A novel model ...

RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). Background: The combination of gemcitabine-cisplatin (GC) is the current standard of care chemotherapy for ...

The odds of cisplatin-induced acute kidney injury decreased with prophylactic administration of intravenous magnesium. Infusing prophylactic magnesium before initiating intravenous cisplatin for ...